Vancomycin Dosing in Patients on Intermittent Hemodialysis

Seminars in Dialysis

Volumn 24, Issue 1, 2011, Pages 50-55

  Vandecasteele, Stefaan J ^a   De Vriese, An S ^a  

^a AZ Sint Jan Brugge Oostende AV ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; GRAM POSITIVE INFECTION; HUMAN; METHODOLOGY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 79951781855     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00803.x     Document Type: Article

References (42)

1. Matzke GR, Zhanel GG, Guay DR: Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11:257-282, 1986
2. Jones RN: Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42(Suppl 1):S13-S24, 2006
3. Vandecasteele SJ, De Vriese AS: Recent changes in vancomycin use in renal failure. Kidney Int 77:760-764, 2010
4. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98, 2009
5. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42(Suppl 1):S35-S39, 2006
6. Levine DP: Vancomycin: a history. Clin Infect Dis 42(Suppl 1):S5-S12, 2006
7. Lafrance JP, Rahme E, Lelorier J, Iqbal S: Vascular access-related infections: definitions, incidence rates, and risk factors. Am J Kidney Dis 52:982-993, 2008
8. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 4:1388-1400, 2009
9. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients - United States, 2005. MMWR Morb Mortal Wkly Rep 56:197-199, 2007
10. Pallotta KE, Manley HJ: Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 21:63-70, 2008
11. Zvonar R, Natarajan S, Edwards C, Roth V: Assessment of vancomycin use in chronic haemodialysis patients: room for improvement. Nephrol Dial Transplant 23:3690-3695, 2008
12. Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, Corey GR: Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 54:1684-1689, 1998
13. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190-196, 2007
14. Keller F, Horstensmeyer C, Looby M, Borner K, Pommer W, Erdmann K, Giehl M: Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs 17: 19-26, 1994
15. Launay-Vacher V, Izzedine H, Mercadal L, Deray G: Clinical review: use of vancomycin in haemodialysis patients. Crit Care 6:313-316, 2002
16. Matzke GR, McGory RW, Halstenson CE, Keane WF: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437, 1984
17. Moellering RC Jr, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343-346, 1981
18. Pea F, Furlanut M, Negri C, Pavon F, Crapis M, Cristini F, Viale P: Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 53:1863-1867, 2009
19. Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA: Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 27:67-74, 1996
20. Ducharme MP, Slaughter RL, Edwards DJ: Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 16:513-518, 1994
21. Tenover FC, Moellering RC Jr: The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208-1215, 2007
22. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC: Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46:668-674, 2008
23. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43: 925-942, 2004
24. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering R, Eliopoulos GM: Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57:699-704, 2006
25. Forouzesh A, Moise PA, Sakoulas G: Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 53:483-486, 2009
26. Meyer CC, Calis KA: New hemodialysis membranes and vancomycin clearance. Am J Health Syst Pharm 52:2794-2796, 1995
27. Pai AB, Pai MP: Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 61:1812-1816, 2004
28. Barth RH, DeVincenzo N: Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 50:929-936, 1996
29. DeSoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 20:354-360, 1992
30. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA: Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 50:51-55, 1998
31. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD: Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 60:96-104, 2003
32. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA: Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46:681-687, 2005
33. Castellano I, Gonzalez Castillo PM, Covarsi A, Martinez Sanchez J, Suarez Santisteban MA, Gallego S, Marigliano S: Vancomycin dosing in hemodialysis patients. Nefrologia 28:607-612, 2008
34. Schaedeli F, Uehlinger DE: Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis. Clin Pharmacol Ther 63:26-38, 1998
35. Zoer J, Schrander-Van der Meer AM, van Dorp WT: Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci 19:191-196, 1997
36. Bauer LA, Black DJ, Lill JS: Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621-625, 1998
37. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO: Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575-580, 1982
38. Vance-Bryan K, Guay DR, Gilliland SS, Rodfold KA, Rotschafer JC: Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 37:436-440, 1993
39. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 17:256-262, 1997
40. Decker BS, Mueller BA, Sowinski KM: Drug dosing considerations in alternative hemodialysis. Adv Chronic Kidney Dis 14:e17-e26, 2007
41. Golestaneh L, Gofran A, Mokrzycki MH, Chen JL: Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Nephrol 72:286-291, 2009
42. James JK, Palmer SM, Levine DP, Rybak MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 40:696-700, 1996